Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Months Years of Age Living in an Area of High Malaria Transmission in Western Kenya

Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Months Years of Age Living in an Area of High Malaria Transmission in Western Kenya

Objectives

We aim to determine whether Plasmodium falciparum sporozoite vaccine is safe, well tolerated, immunogenic, and efficacious in reducing Pf malaria incidence in infants in an area of high malaria transmission.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

Key facts

  • Dates
    Jan 2016 to Dec 2017
    Funding amount
    $3,300,000
    Country
    • Kenya

MESA tags

  • Methodology
    Product development & clinical research
    Theme(s)
    Immune correlates of protection, Tools for elimination